ETON
NASDAQEton Pharmaceuticals Inc.
Price$28.92+0.98 (+3.51%)
01:30 PM07:45 PM
News · 26 weeks48+11%
2025-12-072026-05-31
Mix2390d
- SEC Filings10(43%)
- Other5(22%)
- Insider4(17%)
- Earnings3(13%)
- Leadership1(4%)
Latest news
25 items- INSIDERSEC Form 3 filed by new insider Matthews Judith M.3 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
- INSIDERPresident & CEO Brynjelsen Sean sold $3,825,717 worth of shares (120,000 units at $31.88), decreasing direct ownership by 13% to 833,694 units (SEC Form 4)4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
- SECSEC Form 144 filed by Eton Pharmaceuticals Inc.144 - Eton Pharmaceuticals, Inc. (0001710340) (Subject)
- INSIDERChief Business Officer Krempa David exercised 87,794 shares at a strike of $2.32 and sold $3,229,923 worth of shares (100,000 units at $32.30), decreasing direct ownership by 33% to 25,249 units (SEC Form 4)4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
- SECEton Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
- PREton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)IMPAVIDO® is the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis caused by specific Leishmania speciesLeishmaniasis is a rare but potentially life-threatening parasitic disease that can cause severe skin lesions or systemic infection involving internal organsExclusive U.S. commercialization rights to IMPAVIDO® take effect September 26, 2026 DEER PARK, Ill., May 19, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced it has entered into a supply and distribution agreement for the Unit
- SECSEC Form 10-Q filed by Eton Pharmaceuticals Inc.10-Q - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
- SECEton Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
- PREton Pharmaceuticals Reports First Quarter 2026 Financial ResultsQ1 2026 product sales of $24.3 million, representing 73% growth over Q1 2025Raising full year revenue guidance - now expect 2026 revenue to exceed $120 million, up from previous guidance of $110 millionQ1 2026 fully diluted GAAP EPS of $0.05, non-GAAP fully diluted EPS of $0.14, and Adjusted EBITDA of $5.7 millionReceived FDA approval for and launched DESMODA™Acquired and relaunched HEMANGEOL®Announced initiation of ET-700 clinical study, the Company's extended-release formulation of zinc acetateReceived FDA clearance to proceed on INCRELEX® label harmonization studyManagement to hold conference call today at 4:30pm ET DEER PARK, Ill., May 14, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals
- PREton Pharmaceuticals to Participate in Upcoming Investor ConferencesDEER PARK, Ill., May 12, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that executive management will participate in three upcoming investor conferences as follows: The 26th Annual B. Riley Securities Investor ConferenceDate: Wednesday, May 20, 2026Location: The Ritz-Carlton, Marina Del Rey, California The 23rd Annual Craig-Hallum Institutional Investor ConferenceDate: Thursday, May 28, 2026Location: Depot Renaissance Hotel Minneapolis, Minnesota Jefferies Global Healthcare ConferenceDate: Thursday, June 4, 2026 at 9:
- PREton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026DEER PARK, Ill., May 04, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2026 financial results on Thursday, May 14, 2026. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Participant Call Link:Click Here Webcast:Click Here In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@eton
- PREton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy DistributionHEMANGEOL is now available exclusively through Anovo Specialty Pharmacy to streamline access and therapy initiationEton has integrated full Eton Cares patient support, including $0 co-pay for eligible commercially insured patients and expanded patient assistance programsHEMANGEOL is the only FDA-approved treatment for infantile hemangioma, a pediatric rare disease that can be time-sensitive DEER PARK, Ill., May 01, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the relaunch of HEMANGEOL®. "We are excited to deliver anoth
- SECEton Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
- PREton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700DEER PARK, Ill., April 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the first patient has been dosed in a pilot clinical study assessing the efficacy of ET-700, the Company's proprietary, patent-pending formulation of extended-release zinc acetate under development for the treatment of Wilson disease. Topline study results are expected in the second half of 2026, and if positive, would lead to a pivotal clinical study in early 2027. "ET-700 has the potential to deliver a major advancement for patients with Wilson di
- SECSEC Form DEF 14A filed by Eton Pharmaceuticals Inc.DEF 14A - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
- INSIDERSEC Form 4 filed by Riedel Norbert G4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
- SECEton Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
- PREton Pharmaceuticals Announces CFO Succession PlanDEER PARK, Ill., April 16, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of Judith "Judy" M. Matthews as Executive Vice President, Accounting and Finance. Ms. Matthews will assume the role of Chief Financial Officer effective June 1, 2026. The Company's current Chief Financial Officer, James Gruber, will then step down as part of a planned succession. To ensure a seamless transition, Mr. Gruber will remain in his role through May 31, 2026, and will subsequently enter into a six-month consulting agreement
- SECEton Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Eton Pharmaceuticals Inc.SCHEDULE 13G/A - Eton Pharmaceuticals, Inc. (0001710340) (Subject)
- SECSEC Form 10-K filed by Eton Pharmaceuticals Inc.10-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
- SECEton Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
- PREton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial ResultsQ4 2025 product sales of $21.3 million, representing 83% growth over Q4 2024Q4 2025 basic GAAP EPS of $0.06, fully diluted GAAP EPS of $0.05, basic non-GAAP EPS of $0.21, fully diluted non-GAAP EPS of $0.19, and Adjusted EBITDA of $6.2 millionLaunched DESMODA™, the first and only FDA-approved desmopressin oral solutionLicensed U.S. rights to Orphan Drug HEMANGEOL®; expected to be accretive to 2026 earningsCompany expects full year 2026 revenue to exceed $110 million with an Adjusted EBITDA margin of over 30%Management to hold conference call today at 4:30pm ET DEER PARK, Ill., March 19, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovati
- SECSEC Form S-8 filed by Eton Pharmaceuticals Inc.S-8 - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
- PREton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026DEER PARK, Ill., March 03, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter and full year 2025 financial results on Thursday, March 19, 2026. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Participant Call Link: Click Here Webcast: Click Here In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email
ETON FAQ
7 questionsWhat does Eton Pharmaceuticals Inc. do?
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. It also develops ET-105, a lamotrigine for oral suspension...Where does ETON stock trade?
Eton Pharmaceuticals Inc. (ETON) is listed on NASDAQ.What sector and industry is ETON in?
Eton Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Eton Pharmaceuticals Inc. go public?
Eton Pharmaceuticals Inc. (ETON) completed its IPO in 2018.What are analysts saying about ETON?
Eton Pharmaceuticals Inc. has had 6 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $3300.00 price target on 2025-01-23. Recent price targets range from $800.00 to $3300.00.What companies are similar to ETON?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ETON side-by-side with any of them on Quantisnow.How can I track ETON on Quantisnow?
Quantisnow aggregates Eton Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ETON to receive live email and push alerts on every new disclosure.